Skip to main content
Top
Published in: Clinical Rheumatology 3/2017

01-03-2017 | Brief Report

Refractory ascites in systemic lupus erythematosus: further biological support of intraperitoneal steroid treatment as a suitable therapeutical option

Authors: Yemil Atisha-Fregoso, Diego F Hernández-Ramírez, Elizabeth Olivares-Martínez, Carlos A Núñez-Alvarez, Luis Llorente, Gabriela Hernández-Molina

Published in: Clinical Rheumatology | Issue 3/2017

Login to get access

Abstract

The objective of this report was to evaluate the ascitic fluid of a patient with refractory lupus ascites (proband) at different time points—pre- and post-intraperitoneal treatment with dexamethasone—using a multiparametric approach which included the presence of autoantibodies and pro- and anti-inflammatory cytokines and chemokines, and a proteomic analysis. As controls, we studied two additional patients also with lupus ascites (only at basal evaluation) and two patients with ascites due to alcoholic liver cirrhosis. High levels of anti-dsDNA and anti-nucleosomes autoantibodies were detected in the ascitic fluid of all lupus patients and remained elevated in the proband throughout the follow-up. All lupus patients have detectable ascitic high levels of IL-6, IL-8, IL-10, TNF-α, MCP-1, and IGF-1 which diminished gradually in the proband after intraperitoneal dexamethasone. In the proteomic analysis of the ascitic fluid, a marked increment of apolipoprotein A1 was observed and again, it diminished gradually after intraperitoneal treatment. Our findings further support the use of intraperitoneal steroids as an effective therapeutic option for refractory ascites in systemic lupus erythematosus.
Literature
1.
go back to reference Man B, Mok C (2005) Serositis to systemic lupus erythematosus: prevalence and outcome. Lupus 14:822–826CrossRefPubMed Man B, Mok C (2005) Serositis to systemic lupus erythematosus: prevalence and outcome. Lupus 14:822–826CrossRefPubMed
2.
go back to reference Pott H, Neto A, Barone M et al (2012) Ascitis due to lupus peritonitis: a rare form of onset of systemic lupus erythematosus. Rev Bras Reumatol 52:113–119 Pott H, Neto A, Barone M et al (2012) Ascitis due to lupus peritonitis: a rare form of onset of systemic lupus erythematosus. Rev Bras Reumatol 52:113–119
3.
go back to reference Aljebreen A, Al-Mogairen S (2014) Refractroy ascites as the first presentation of systemic lupus erythematosus. Arab J Gastroenterol 15:161–162CrossRefPubMed Aljebreen A, Al-Mogairen S (2014) Refractroy ascites as the first presentation of systemic lupus erythematosus. Arab J Gastroenterol 15:161–162CrossRefPubMed
4.
go back to reference Rongquan L, Zhang K, Gao S et al (2014) Gastrointestinal symptom due to lupus peritonitis: a rare form of onset of SLE. Int J Clin Exp Med 7:5917–5920 Rongquan L, Zhang K, Gao S et al (2014) Gastrointestinal symptom due to lupus peritonitis: a rare form of onset of SLE. Int J Clin Exp Med 7:5917–5920
5.
go back to reference Ito H, Nahamiya W, Kuroda N et al (2002) Chronic lupus peritonitis with massive ascites at elderly onset: case report and review of the literature. Intern Med 41:1056–1061CrossRefPubMed Ito H, Nahamiya W, Kuroda N et al (2002) Chronic lupus peritonitis with massive ascites at elderly onset: case report and review of the literature. Intern Med 41:1056–1061CrossRefPubMed
6.
go back to reference Zhou Q, Yang X, Hou F et al (2009) Successful treatment of massive ascites with intraperitoneal administration of a steroid in a case of systemic lupus erythematosus. Lupus 8:740–742CrossRef Zhou Q, Yang X, Hou F et al (2009) Successful treatment of massive ascites with intraperitoneal administration of a steroid in a case of systemic lupus erythematosus. Lupus 8:740–742CrossRef
7.
go back to reference Forouhar-Graff H, KA D-Y, Parke A (2011) Insidious onset of massive painless ascites as initial manifestation of systemic lupus erythematosus. Lupus 20:754–757CrossRefPubMed Forouhar-Graff H, KA D-Y, Parke A (2011) Insidious onset of massive painless ascites as initial manifestation of systemic lupus erythematosus. Lupus 20:754–757CrossRefPubMed
9.
go back to reference Watanabe R, Fujii H, Kamogawa Y et al (2015) Chronic lupus peritonitis is characterized by the ascites with a large content of interleukin-6. Tohoku J Exp Med 235:289–294CrossRefPubMed Watanabe R, Fujii H, Kamogawa Y et al (2015) Chronic lupus peritonitis is characterized by the ascites with a large content of interleukin-6. Tohoku J Exp Med 235:289–294CrossRefPubMed
10.
go back to reference Lee MJ, Shin DH, Ko KI et al (2013) Association between the ratio of insulin-like growth factor-I to insulin-like growth factor binding protein-3 and inflammation in incident automated peritoneal dialysis patients. Growth Hormon IGF Res 23:170–174CrossRef Lee MJ, Shin DH, Ko KI et al (2013) Association between the ratio of insulin-like growth factor-I to insulin-like growth factor binding protein-3 and inflammation in incident automated peritoneal dialysis patients. Growth Hormon IGF Res 23:170–174CrossRef
11.
go back to reference Peng H, Wang W, Zhou M et al (2013) Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus. Clin Rheumatol 32:1255–1266CrossRefPubMed Peng H, Wang W, Zhou M et al (2013) Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus. Clin Rheumatol 32:1255–1266CrossRefPubMed
12.
go back to reference Antonelli A, Ferrari SM, Giuggioli D et al (2014) Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 13:272–280CrossRefPubMed Antonelli A, Ferrari SM, Giuggioli D et al (2014) Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 13:272–280CrossRefPubMed
13.
go back to reference Gupta R, Misra SP, Dwivedi M et al (2001) Diagnosing ascites: value of ascitic fluid total protein, albumin, cholesterol, their ratios, serum-ascites albumin and cholesterol gradient. J Gastroenterol Hepatol 10:295–299CrossRef Gupta R, Misra SP, Dwivedi M et al (2001) Diagnosing ascites: value of ascitic fluid total protein, albumin, cholesterol, their ratios, serum-ascites albumin and cholesterol gradient. J Gastroenterol Hepatol 10:295–299CrossRef
14.
go back to reference Jüngst D, Xie Y, Gerbes AL (1992) Pathophysiology of elevated ascites fluid cholesterol in malignant ascites. Increased ascites to serum relation of proteins and lipoproteins in patients with peritoneal carcinomatosis as compared to patients with cirrhosis of the liver. J Hepatol 14:244–248CrossRefPubMed Jüngst D, Xie Y, Gerbes AL (1992) Pathophysiology of elevated ascites fluid cholesterol in malignant ascites. Increased ascites to serum relation of proteins and lipoproteins in patients with peritoneal carcinomatosis as compared to patients with cirrhosis of the liver. J Hepatol 14:244–248CrossRefPubMed
15.
go back to reference Wiig H, Swartz MA (2012) Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev 92:1005–1060CrossRefPubMed Wiig H, Swartz MA (2012) Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev 92:1005–1060CrossRefPubMed
16.
go back to reference Hyka N, Dayer JM, Modoux C et al (2001) Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97:2381–2389CrossRefPubMed Hyka N, Dayer JM, Modoux C et al (2001) Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97:2381–2389CrossRefPubMed
17.
go back to reference Wilhelm AJ, Zabalawi M, Owen JS et al (2010) Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr−/−, ApoA-I−/− mice. J Biol Chem 285:36158–36169CrossRefPubMedPubMedCentral Wilhelm AJ, Zabalawi M, Owen JS et al (2010) Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr−/−, ApoA-I−/− mice. J Biol Chem 285:36158–36169CrossRefPubMedPubMedCentral
18.
go back to reference Provenzano G, Rinaldi F, Le Moli S et al (1993) Chronic lupus peritonitis responsive to treatment with cyclophosphamide. Br J Rheumatol 32:1116CrossRefPubMed Provenzano G, Rinaldi F, Le Moli S et al (1993) Chronic lupus peritonitis responsive to treatment with cyclophosphamide. Br J Rheumatol 32:1116CrossRefPubMed
19.
go back to reference Shcousboe J, Koch A, Chang R (1998) Chronic lupus peritonitis with ascitis: review of the literature with a case report. Semin Arthritis Rheu 18:121–126 Shcousboe J, Koch A, Chang R (1998) Chronic lupus peritonitis with ascitis: review of the literature with a case report. Semin Arthritis Rheu 18:121–126
Metadata
Title
Refractory ascites in systemic lupus erythematosus: further biological support of intraperitoneal steroid treatment as a suitable therapeutical option
Authors
Yemil Atisha-Fregoso
Diego F Hernández-Ramírez
Elizabeth Olivares-Martínez
Carlos A Núñez-Alvarez
Luis Llorente
Gabriela Hernández-Molina
Publication date
01-03-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3473-9

Other articles of this Issue 3/2017

Clinical Rheumatology 3/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.